NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, June 14, 2019 (GLOBE NEWSWIRE) -- Canada House Wellness Group Inc. (CSE: CHV) (“Canada House” or the “Company”), a fully integrated medical cannabis company, is pleased to provide an update on clinic expansion by its wholly owned subsidiary Canada House Clinics Inc. (“CHC”).
CHC will open its first clinics in Toronto and Halifax, relocate its Petawawa clinic to a larger space and launch a new clinic model in Edmonton. Once the new spaces open, CHC will operate 14 clinics across Canada.
“We strive to continuously improve the patient experience,” said Alex Kroon, President, Canada House Clinics. “There is a process involved in cannabinoid therapy and patients are looking for guidance. CHC is committed to offering different models to meet patient needs and increase access for all Canadians requiring medical cannabis therapy.”
Canada House Clinics’ first Toronto clinic will open on June 17, 2019 in the Champagne Centre (a multidisciplinary medical complex) in North York. The Champagne Centre is an innovative 270,000 square foot health, sports, and wellness complex that includes the PolyClinic Family and Specialty Medicine Facility.
CHC will open its Halifax clinic on July 3, 2019, building on the strong network of clinics already operating in Atlantic Canada.
CHC moved its Petawawa location to a larger clinic in the same area on June 10, 2019.
This summer in Sherwood Park, Alberta, CHC will open its first location within a third-party medical clinic (an embedded clinic model). CHC will operate an office inside an existing medical clinic. Doctors can offer cannabinoid therapy to their patients. This first embedded clinic will be CHC’s second location in the Edmonton area. CHC plans to replicate this embedded clinic model in other cities.
“Our clinic footprint continues to grow across Canada,” said Chris Churchill-Smith, CEO, Canada House. “Smart, targeted clinic expansion will reduce our operating expenses, continue to accelerate growth, drive profitability, build shareholder value and help us continue to meet the needs of Canadian patients.”
About Canada House Wellness Group Inc.
Canada House Wellness Group Inc. is the parent company of Abba Medix Corp., a Licensed Producer in Pickering, Ontario that produces high quality medical grade cannabis; Canada House Clinics Inc., with clinics across the country that work directly with primary care teams to provide specialized cannabinoid therapy services to patients suffering from complex medical conditions; and Knalysis Technologies, a provider of fully customizable, cloud-based software that links physician, provider, and patient to data that supports treatment with medical cannabis.
Canada House Wellness Group’s goal is to become the leading cultivator of premium craft cannabis and provider of cannabinoid therapy, targeting the medical cannabis markets globally.
For more information please visit www.canadahouse.ca.
For further information, please contact:
Liana Del Medico, Director of Communications & Investor Relations
Canada House Wellness Group Inc.
289-980-3584
liana.delmedico@canadahouse.ca
Cautionary Statement Regarding Forward-Looking Information. This press release contains forward-looking statements, including statements that relate to, among other things, the Company’s clinic, production and technology businesses, its future plans, the Company’s markets, objectives, goals, strategies, intentions, beliefs, expectations and estimates, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Material assumptions used to develop forward-looking information in this news release include, among other things, the regulations related to cannabis use under the Access to Cannabis for Medical Purposes Regulations and the act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts, passed by the Canadian Federal government, making cannabis legal for recreational use by October 17, 2018; Company liquidity and capital resources, including the availability of additional capital resources to fund its activities; level of competition; the ability to adapt products and services to the changing market; the ability to attract and retain key executives; and the ability to execute strategic plans. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.